Nov 192004
 

While this isn’t exactly cutting edge news I finally got around to reading about RPI-78M an experimental drug for Multiple Sclerosis – articles here. While we are certainly a ways from a clinical trial if this really lives up to these levels I agree that it will revolutionize MS treatment. “RPI-78M reduced the clinical symptoms by more than 80%,” remarked neurologist Mitchell S. Felder, MD “There was also more than an 87% reduction in the number of EAE histopathologic lesions.” Since I am not all that pleased with my performance on Rebif maybe when this comes out I can go on the Rebif + Copaxone + Antegren + RPI-78M. Of course with my insurance rates getting out of control I am pretty sure I couldn’t afford that. 🙁

 Posted by at 10:20 pm

  One Response to “RPI-78M”

  1. Update on RPI-78M

    ERDI was contracted by Nutra Pharma to analyze immune cells and brain lesions of Multiple Sclerosis patients with and without the addition of RPI-78M. They measured the changes in gene expression that occurred with treatment. After statistical evaluation of the data, ERDI found more than sixty genes with significant changes in expression as compared to the control. In analyzing the affected genes, at least thirty of them may have a specific role in the progression of the disease and symptoms of MS.

    “RPI-78M had a significant affect on the genes in the cytokine pathway as well as the myelination pathway,” commented James Flowers, President and Chief Scientific Officer of Eno Research and Development, Inc. (ERDI). “The cytokine pathway genes play a role in marshaling the attack on the nervous system by immune cells. Since this is one of the principle pathways that lead to the forward progression of MS, it is notable that if these results were replicated in the patient population it may greatly reduce the severity of the disease” he continued. “Additionally, genes responsible for repair and maintenance of the myelin sheathes of neurons were upregulated. MS patients have a loss of myelin, the insulating material that surrounds the nerve fibers in the brain, spinal cord, and optic nerves. This damage or loss of myelin can prevent nerve signals from being conducted, or can cause those signals to be conducted too slowly. The data from this study suggests that RPI-78M may aid the patient in reversing some of the damage caused to the myelin by their disease.” ERDI will continue to study RPI-78M and its effects on gene expression as well as the drug’s effects in histoculture experiments that may further elucidate its mechanism of action.

    There has been a great deal of interest surrounding research in Multiple Sclerosis therapies. There are currently four drugs on the market for the treatment of the disease. A fifth drug, Tysabri, was voluntarily pulled from the marketplace earlier this week by the drug’s manufacturers, Biogen-Idec and Elan.

 Leave a Reply

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

(required)

(required)

*